title: Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia.
abstract: OBJECTIVE
  To describe baseline characteristics and clinical outcomes of older adults with pneumococcal bacteremia, compare the frequency of serious outcomes according to pneumococcal vaccination status, and assess factors associated with mortality.
  
  
  METHODS
  Population-based case-series.
  
  
  METHODS
  Group Health Cooperative, a health maintenance organization in Washington State.
  
  
  METHODS
  Community-dwelling adults aged 65 and older with a first episode of pneumococcal bacteremia between 1988 and 2002.
  
  
  METHODS
  Demographic characteristics, underlying medical conditions, vaccination status, and clinical outcomes, including death, hospitalization, length of hospital stay, and postdischarge care, were assessed using chart review.
  
  
  RESULTS
  The mean age of the 200 elderly patients with pneumococcal bacteremia was 78; 61% were female. Forty percent had had chart-documented pneumococcal vaccination before the onset of bacteremia. The spectrum of clinical severity and consequences was broad. Ten percent were treated as outpatients. Of the 90% who were hospitalized, 16% were admitted to the intensive care unit. All-cause mortality at 30 days was 11%. Of survivors, 23% were discharged with home services, and another 20% were discharged to a nursing home. After controlling for age, sex, and pneumococcal vaccination status, predictors of death included coronary artery disease (odds ratio (OR)=4.6, 95% confidence interval (CI)=1.4-14.5) and immunocompromising conditions (OR=5.0, 95% CI=1.6-15.7). Outcomes were similar in patients who did and did not receive pneumococcal vaccination.
  
  
  CONCLUSIONS
  In this elderly group, pneumococcal bacteremia was associated with substantial morbidity, mortality, and loss of independence. Coronary artery disease and immunocompromising conditions were independent predictors of death.
authors.affiliation: Division of Gerontology and Geriatric Medicine, Department of Medicine, School of Medicine, University of Washington, Seattle, Washington, USA. rchi@u.washington.edu
authors.forename: Ru-Chien
authors.initials: RC
authors.lastname: Chi
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Jackson
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Neuzil
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016470:Bacteremia / Q000150:complications / Q000401:mortality* / Q000628:therapy*; D017714:Community-Acquired Infections / Q000150:complications / Q000401:mortality / Q000628:therapy; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000150:complications / Q000401:mortality* / Q000628:therapy*; D022242:Pneumococcal Vaccines; D012111:Residence Characteristics; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D022242:Pneumococcal Vaccines